BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33883177)

  • 1. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
    Curigliano G; Gelderblom H; Mach N; Doi T; Tai D; Forde PM; Sarantopoulos J; Bedard PL; Lin CC; Hodi FS; Wilgenhof S; Santoro A; Sabatos-Peyton CA; Longmire TA; Xyrafas A; Sun H; Gutzwiller S; Manenti L; Naing A
    Clin Cancer Res; 2021 Jul; 27(13):3620-3629. PubMed ID: 33883177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
    Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
    Schöffski P; Tan DSW; Martín M; Ochoa-de-Olza M; Sarantopoulos J; Carvajal RD; Kyi C; Esaki T; Prawira A; Akerley W; De Braud F; Hui R; Zhang T; Soo RA; Maur M; Weickhardt A; Krauss J; Deschler-Baier B; Lau A; Samant TS; Longmire T; Chowdhury NR; Sabatos-Peyton CA; Patel N; Ramesh R; Hu T; Carion A; Gusenleitner D; Yerramilli-Rao P; Askoxylakis V; Kwak EL; Hong DS
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
    Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
    Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
    Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
    Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
    ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
    Harding JJ; Moreno V; Bang YJ; Hong MH; Patnaik A; Trigo J; Szpurka AM; Yamamoto N; Doi T; Fu S; Calderon B; Velez de Mendizabal N; Calvo E; Yu D; Gandhi L; Liu ZT; Galvao VR; Leow CC; de Miguel MJ
    Clin Cancer Res; 2021 Apr; 27(8):2168-2178. PubMed ID: 33514524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
    Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase Ib/II trial of capmatinib plus spartalizumab
    Santoro A; Assenat E; Yau T; Delord JP; Maur M; Knox J; Cattan S; Lee KH; Del Conte G; Springfeld C; Leo E; Xyrafas A; Fairchild L; Mardjuadi F; Chan SL
    JHEP Rep; 2024 Apr; 6(4):101021. PubMed ID: 38617599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
    Felip E; Moreno V; Morgensztern D; Curigliano G; Rutkowski P; Trigo JM; Calvo A; Kowalski D; Cortinovis D; Plummer R; Maio M; Ascierto PA; Vladimirov VI; Cervantes A; Zudaire E; Hazra A; T'jollyn H; Bandyopadhyay N; Greger JG; Attiyeh E; Xie H; Calvo E
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):499-514. PubMed ID: 35298698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
    Chan SL; Schuler M; Kang YK; Yen CJ; Edeline J; Choo SP; Lin CC; Okusaka T; Weiss KH; Macarulla T; Cattan S; Blanc JF; Lee KH; Maur M; Pant S; Kudo M; Assenat E; Zhu AX; Yau T; Lim HY; Bruix J; Geier A; Guillén-Ponce C; Fasolo A; Finn RS; Fan J; Vogel A; Qin S; Riester M; Katsanou V; Chaudhari M; Kakizume T; Gu Y; Porta DG; Myers A; Delord JP
    J Exp Clin Cancer Res; 2022 Jun; 41(1):189. PubMed ID: 35655320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
    Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.
    Minami H; Doi T; Toyoda M; Imamura Y; Kiyota N; Mitsuma A; Shimokata T; Naito Y; Matsubara N; Tajima T; Tokushige K; Ishihara K; Cameron S; Ando Y
    Cancer Sci; 2021 Feb; 112(2):725-733. PubMed ID: 33031626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
    Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
    Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
    Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
    Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
    Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L
    Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
    Patel SP; Alonso-Gordoa T; Banerjee S; Wang D; Naidoo J; Standifer NE; Palmer DC; Cheng LY; Kourtesis P; Ascierto ML; Das M; Diamond JR; Hellmann MD; Carneiro BA
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.